Aquos Dry Eye Center

The Aquos Dry Eye Center is an ophthalmologist (eye medical doctor)-led specialty diagnostic and treatment center for the care of dry eye disease and blepharitis. Our mission is to serve patients that are often not sufficiently treated by a standard eye exam and provide them with comprehensive care. Previously, there were fewer options for management as there are today, and many patients who were diagnosed with dry eye were sent away with a recommendation for artificial tears. This only controls the mildest cases, and patients continue to suffer. Many patients are either underdiagnosed or under-treated for dry eye, blepharitis, and other associated conditions.

Dr. Salvay recognized that many of these conditions dramatically affect patient quality of life. Dr. Salvay believes that the most important aspect of the doctor-patient relationship is excellent and honest communication. During each visit, Dr. Salvay will take the time to go over his findings with you and answer any questions you may have regarding your eye issues and treatment plan.

Dr. Salvay is a member of the American Academy of Ophthalmology and the American Society of Cataract & Refractive Surgery. He offers a full range of medical and surgical eye care services, including medical management of glaucoma, macular degeneration, diabetic eye disease, ocular trauma and dry eye disease. He specializes in surgery for cataracts, glaucoma, functional eyelid disorders as well as laser treatment and injections for many different types of ocular diseases.

Once he arrived in Newport Beach, in concert with Dr. David Wirta, he elected to create a center that would combine that patient centered focus with the technological expertise, and the opportunity to advance the field with FDA approved clinical research trials. This was the birth of the Aquos Dry Eye Center. At the Aquos Dry Eye Center, we recognize that there are multiple different causes for dry eye. Many patients may actually suffer from Sjogren’s disease which can be associated with other problems in the body such as lymphoma. There is also a major distinction in dry eye between a lack of tears and problems with the tears evaporating too quickly.

From the beginning to the end of the appointment in the Aquos Dry Eye Center, we will focus on the diagnosis, assessment, and treatment of you as a patient who suffers with dry eye. On your first appointment, you will initially complete two research validated dry eye surveys, and Dr. Salvay will assess you with several objective dry eye measurements. Depending on your type of dry eye he will consider various pharmacological, environmental, and procedural treatments. If you are interested, you may also have the opportunity to participate in FDA approved clinical research trials. Some of our procedural offerings include punctal plugs, meibomian gland probing, and meibomian gland expression. If you think you may have dry eye or have someone to refer, please call 949-650-1863 and ask for an appointment in the Aquos Dry Eye Center.

Q & A With Dr. Salvay

Dry Eye is a disorder characterized by decreased tear production or increased tear evaporation such as blepharitis that results in symptoms such as dryness, burning, stinging, feeling like something is in the eye, sensitivity to light, blurry vision, difficulty with contact lenses, or watering eyes. The tear film is made up of a water layer that we call the aqueous layer, a lipid layer and a mucin layer.
There are a multitude of treatments for dry eye including artificial tears, medications such as restasis, steroids; antibiotics such as doxycycline, natural remedies such as fish oil; plugs to close the typical drainage of the tears, gland expression and probing, tears made of your own blood, etc. Each of these treatments address certain layers of the tear film.
You should be checked for dry eye if you are having the above symptoms.
We currently are in a dry eye renaissance with new medications that are being researched including novel medications. They are really broken into anti-inflammatory medications such as lifitegrast that inhibits t-cell inflammation, topical IL-1 receptor blockers, different formulations of cyclosporine which is currently used in restasis, and rebamipide, diquafosol which causes mucin secretion, RU-101 which is recombinant human serum which is similar to serum that we make from blood currently.